Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Maximize your trial’s chances of success with best-in-class clinical trial data and benchmarks.
An effective clinical drug development program strategy requires optimal trial protocol development, operations planning and execution and a clear understanding of the clinical trial landscape. To support success and understand the competition, you need access to relevant, timely clinical trial data and trial benchmarks.
You also need to know where you can find reliable details of competitor and comparator trials as well as information on investigators and sites.
How we can help
It can be very time-consuming to source, review, and analyze available clinical trial data. Parsing through large amounts of information to find the relevant and key insights can also be a frustrating task.
Our easy-to-use products help you quickly filter thousands of trials to find the most relevant set to inform your trial and program strategy – from protocol design to country and principal investigator selection.
We’ll also help you:
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.
Key benefits:
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Key benefits:
Citeline
10 Jan 2020
Get a deeper understanding of breast cancer clinical trials initiated since 2014 and what the trends have meant for strategies in this area, with this free whitepaper from Citeline.
Topic Cancer Clinical Trials Research
Trialtrove
21 Nov 2019
A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.
Topic Drug Development Landscape BioPharmaceutical Business Strategies
Citeline Engage
By Pharma Intelligence 15 Nov 2019
Case Study: A Top 5 CRO partners with Informa Pharma Intelligence to mitigate risk, identify and recruit untapped investigators, and accelerate timelines
Trialtrove
24 Oct 2019
Review the trends, diseases, sponsors and outcomes involved with recent patient-centric clinical trials.
Topic Clinical trials
Trialtrove
24 Oct 2019
Patient-centric trials have been growing for years. Backed by data from Citeline’s Trialtrove, our latest infographic reveals the trends, the sponsors, and the impact on outcomes around Phase I, II, and III industry-sponsored, patient-centric trials.
Trialtrove
11 Oct 2019
See last year’s clinical trial activity through the eyes of our expert analysts and get a better sense of where the industry is headed. This new whitepaper is the annual analysis of Phase I-III clinical trials, from Citeline’s Trialtrove, and reveals the priorities and strategies of the biopharma industry.
Topic Drug development landscape BioPharmaceutical Business strategies
Citeline
26 Sep 2019
To increase flexibility and efficiency in drug development, master protocols have emerged as an innovative clinical trial design, including basket and umbrella trials. Learn more about how these approaches are being used within oncology research through an overview of the clinical landscape, trial outcomes and trends.
Citeline, Pink Sheet
26 Sep 2019
Rising costs, patient recruitment issues, shifting regulations, and more are making bringing new drugs to market more difficult than ever. Explore changes in clinical trial design being adopted in response to these challenges with reporting from Pink Sheet.
Citeline
By Jonathan Slater 02 Sep 2019
The Generating Antibiotic Incentives Now (GAIN) Act passed into law on July 9, 2012. Seven years on, we review the drugs that have obtained QIDP status, the companies involved, and the clinical trial landscape.
Trialtrove
12 Aug 2019
Get a visual snapshot of how the industry pipelines are faring with our 2018 Completed Trials snapshot. This graphic analysis paints a clear picture of the state of clinical trial completions, while pointing to some important changes that are emerging.
Trialtrove
06 Aug 2019
The landscape of trials initiated by industry sponsors is one metric that informs about the R&D health of the biopharma industry. Looking specifically at trial completions adds a layer of granularity to the trials landscape and provides valuable perspective on how well industry pipelines are faring. As Informa Pharma has done for the past four years, we report the results from our analysis of the landscape of clinical trials completed during 2018.
Citeline
30 Jul 2019
KNect365 Life Sciences recently conducted a survey into the clinical trial industry at its most interesting point to date, as organisations are implementing new technologies and trends such as AI, virtual trials and wearables. The final report, based on 214 responses, reveals unique insights into what current benefits and challenges companies are facing in the processes of applying these new approaches to therapeutic development. Citeline introduces the report, exploring what some of the key takeaways mean for the industry.
Citeline
03 Jul 2019
With opioid abuse and deaths in the US at an all-time high, the journey to battle the opioid epidemic continues – keeping drug companies and the FDA working hard to come up with effective alternatives for pain.
Topic Drug approval Drug review
Citeline, Pharmaprojects
02 Jul 2019
For a snapshot of the new active substances (NAS) successfully launched last year, download the data-packed New Active Substances (NAS) Launched During 2018 infographic from Citeline.
Pharmaprojects
02 Jul 2019
The discovery and deep investigation of the microbiome has been one of the most significant recent biomedical advances. Extensive research suggests that dysbiosis of the gut microbiome plays a significant role in multiple gastrointestinal (GI) disorders such as; Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS).
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
